Tesla Raises Cybertruck Prices by $5,000 in US 
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny 
Nvidia Revenue Soars 106% as AI Demand Hits ‘Inflection Point’ 
Yindjibarndi Appeals Fortescue Mining Compensation Ruling 
Adidas, Puma Shares Fall as Dick’s Sporting Goods Cuts Outlook 
BofA Names ASML Top Semiconductor Equipment Pick on Growth, Valuation 
Mercer International Stock Surges 45% on C$20 Million Canada Funding 
Xiaomi Unveils Xring O3 Chip for Flagship Foldable Phone 
BNP Paribas, KB Kookmin Eye $2 Billion Techcombank Stake 
J.P. Morgan Upgrades Diploma, Lifts Price Target to 8,250p 
SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim 
Meta, U.S. States Discuss Settlement in Teen Addiction Trial 
Salesforce Shares Surge as AI Demand Powers Q2 Earnings Beat 
Trian Drops Wendy’s Take-Private Bid Plans, Shares Plunge 14% 
Luxshare Shares Rise as First-Half Profit Jumps 18% 
Trump Administration Plans New Drug Pricing Deals With Biotech Firms 
Add as a preferred source on Google
CARMIEL, Israel, April 26, 2018 -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced that it will report first quarter 2018 financial results and provide a corporate update on Wednesday, May 9, 2018 at 8:30 am ET.
To participate in the conference call, please dial the following numbers prior to the start of the call: United States: +1-844-358-6760; International: +1-478-219-0004. Conference ID number 8190507.
The conference call will also be broadcast live and available for replay for two weeks on the Company’s website, www.protalix.com, in the Events Calendar of the Investors section. Please access the Company’s website at least 15 minutes ahead of the conference to register, download, and install any necessary audio software.
About Protalix BioTherapeutics, Inc.
Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®. Protalix’s unique expression system presents a proprietary method for developing recombinant proteins in a cost-effective, industrial-scale manner. Protalix’s first product manufactured by ProCellEx, taliglucerase alfa, was approved for marketing by the U.S. Food and Drug Administration (FDA) in May 2012 and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights. Protalix’s development pipeline includes the following product candidates: pegunigalsidase alfa, a modified version of the recombinant human alpha-GAL-A protein for the treatment of Fabry disease; OPRX-106, an orally-delivered anti-inflammatory treatment; alidornase alfa for the treatment of Cystic Fibrosis; and others. Protalix has entered into an ex-United States partnership with Chiesi Farmaceutici S.p.A. for the development and commercialization of pegunigalsidase alfa. Protalix maintains full rights to pegunigalsidase alfa in the United States.
Investor Contact
Marcy Nanus
Solebury Trout
646-378-2927
[email protected]
